Literature DB >> 21505144

Molecular characterization of skeletal muscle atrophy in the R6/2 mouse model of Huntington's disease.

Pengxiang She1, Zhiyou Zhang, Deanna Marchionini, William C Diaz, Thomas J Jetton, Scot R Kimball, Thomas C Vary, Charles H Lang, Christopher J Lynch.   

Abstract

Huntington's disease (HD), a neurodegenerative disorder caused by mutant huntingtin, is characterized by a catabolic phenotype. To determine the mechanisms underlying muscle wasting, we examined key signal transduction pathways governing muscle protein metabolism, apoptosis, and autophagy in R6/2 mice, a well-characterized transgenic model of HD. R6/2 mice exhibited increased adiposity, elevated energy expenditure, and decreased body weight and lean mass without altered food intake. Severe skeletal muscle wasting accounted for a majority of the weight loss. Protein synthesis was unexpectedly increased 19% in gastrocnemius muscle, which was associated with overactivation of basal and refeeding-stimulated mammalian target of rapamycin (mTOR) signaling, elevated Akt expression and Ser(473) phosphorylation, and decreased AMPK Thr(172) phosphorylation. Moreover, mRNA abundance of atrogenes muscle ring finger-1 and atrophy F-box, was markedly attenuated during fasting and refeeding, and the urinary excretion of 3-methylhistidine was decreased, arguing against a role for the ubiquitin proteasome-mediated proteolysis in the atrophy. In contrast, mRNA expression of several caspase genes and genes involved in the extrinsic or intrinsic apoptotic pathway, caspase-3/7, -8, and -9 activity, protein abundance of caspase-3 and -9, Fas, and Fadd, and cytochrome c release were elevated. Protein expressions of LC3B-I and -II, beclin-I, and atg5 and -7 in muscle were upregulated. Thus, mutant huntingtin in skeletal muscle results in increased protein synthesis and mTOR signaling, which is countered by activation of the apoptotic and autophagic pathways, contributing to an overall catabolic phenotype and the severe muscle wasting.

Entities:  

Mesh:

Year:  2011        PMID: 21505144      PMCID: PMC3129844          DOI: 10.1152/ajpendo.00630.2010

Source DB:  PubMed          Journal:  Am J Physiol Endocrinol Metab        ISSN: 0193-1849            Impact factor:   4.310


  73 in total

1.  Activation of caspase-3 is an initial step triggering accelerated muscle proteolysis in catabolic conditions.

Authors:  Jie Du; Xiaonan Wang; Christiane Miereles; James L Bailey; Richard Debigare; Bin Zheng; S Russ Price; William E Mitch
Journal:  J Clin Invest       Date:  2004-01       Impact factor: 14.808

Review 2.  Apoptosis signalling is essential and precedes protein degradation in wasting skeletal muscle during catabolic conditions.

Authors:  Josep M Argilés; Francisco J López-Soriano; Sílvia Busquets
Journal:  Int J Biochem Cell Biol       Date:  2008-02-14       Impact factor: 5.085

3.  Glucocorticoids activate the ATP-ubiquitin-dependent proteolytic system in skeletal muscle during fasting.

Authors:  S S Wing; A L Goldberg
Journal:  Am J Physiol       Date:  1993-04

4.  Importance of the ATP-ubiquitin-proteasome pathway in the degradation of soluble and myofibrillar proteins in rabbit muscle extracts.

Authors:  V Solomon; A L Goldberg
Journal:  J Biol Chem       Date:  1996-10-25       Impact factor: 5.157

5.  Role of different proteolytic systems in the degradation of muscle proteins during denervation atrophy.

Authors:  K Furuno; M N Goodman; A L Goldberg
Journal:  J Biol Chem       Date:  1990-05-25       Impact factor: 5.157

6.  The metabolic profile of early Huntington's disease--a combined human and transgenic mouse study.

Authors:  Anna O G Goodman; Peter R Murgatroyd; Gema Medina-Gomez; Nigel I Wood; Nicholas Finer; Antonio J Vidal-Puig; A Jennifer Morton; Roger A Barker
Journal:  Exp Neurol       Date:  2008-01-19       Impact factor: 5.330

Review 7.  Ntau-methylhistidine (3-methylhistidine) and muscle protein turnover: an overview.

Authors:  V R Young; H N Munro
Journal:  Fed Proc       Date:  1978-07

8.  A practical and reliable method for determination of urinary 3-methylhistidine.

Authors:  H Vielma; J Mendez; M Druckenmiller; H Lukaski
Journal:  J Biochem Biophys Methods       Date:  1981-08

9.  Autophagy regulates the processing of amino terminal huntingtin fragments.

Authors:  Zheng-Hong Qin; Yumei Wang; Kimberly B Kegel; Aleksey Kazantsev; Barbara L Apostol; Leslie Michels Thompson; Jennifer Yoder; Neil Aronin; Marian DiFiglia
Journal:  Hum Mol Genet       Date:  2003-10-21       Impact factor: 6.150

10.  Increase in bax expression and apoptosis are associated in Huntington's disease progression.

Authors:  A V F F Teles; T R Rosenstock; C S Okuno; G S Lopes; C R A Bertoncini; S S Smaili
Journal:  Neurosci Lett       Date:  2008-03-27       Impact factor: 3.046

View more
  38 in total

Review 1.  Energy dysfunction in Huntington's disease: insights from PGC-1α, AMPK, and CKB.

Authors:  Tz-Chuen Ju; Yow-Sien Lin; Yijuang Chern
Journal:  Cell Mol Life Sci       Date:  2012-05-25       Impact factor: 9.261

Review 2.  Choosing an animal model for the study of Huntington's disease.

Authors:  Mahmoud A Pouladi; A Jennifer Morton; Michael R Hayden
Journal:  Nat Rev Neurosci       Date:  2013-10       Impact factor: 34.870

3.  Overexpression of smooth muscle myosin heavy chain leads to activation of the unfolded protein response and autophagic turnover of thick filament-associated proteins in vascular smooth muscle cells.

Authors:  Callie S Kwartler; Jiyuan Chen; Dhananjay Thakur; Shumin Li; Kedryn Baskin; Shanzhi Wang; Zhao V Wang; Lori Walker; Joseph A Hill; Henry F Epstein; Heinrich Taegtmeyer; Dianna M Milewicz
Journal:  J Biol Chem       Date:  2014-04-07       Impact factor: 5.157

4.  The Expanding Clinical Universe of Polyglutamine Disease.

Authors:  Shanshan Huang; Suiqiang Zhu; Xiao-Jiang Li; Shihua Li
Journal:  Neuroscientist       Date:  2019-01-07       Impact factor: 7.519

5.  Reinstating aberrant mTORC1 activity in Huntington's disease mice improves disease phenotypes.

Authors:  John H Lee; Luis Tecedor; Yong Hong Chen; Alex Mas Monteys; Matthew J Sowada; Leslie M Thompson; Beverly L Davidson
Journal:  Neuron       Date:  2014-12-31       Impact factor: 17.173

6.  Depressed Synaptic Transmission and Reduced Vesicle Release Sites in Huntington's Disease Neuromuscular Junctions.

Authors:  Ahmad Khedraki; Eric J Reed; Shannon H Romer; Qingbo Wang; William Romine; Mark M Rich; Robert J Talmadge; Andrew A Voss
Journal:  J Neurosci       Date:  2017-07-19       Impact factor: 6.167

Review 7.  Mechanisms for fiber-type specificity of skeletal muscle atrophy.

Authors:  Yichen Wang; Jeffrey E Pessin
Journal:  Curr Opin Clin Nutr Metab Care       Date:  2013-05       Impact factor: 4.294

Review 8.  Potassium channel dysfunction in neurons and astrocytes in Huntington's disease.

Authors:  Xiao Zhang; Jie-Qing Wan; Xiao-Ping Tong
Journal:  CNS Neurosci Ther       Date:  2018-01-27       Impact factor: 5.243

9.  Huntington disease skeletal muscle is hyperexcitable owing to chloride and potassium channel dysfunction.

Authors:  Christopher W Waters; Grigor Varuzhanyan; Robert J Talmadge; Andrew A Voss
Journal:  Proc Natl Acad Sci U S A       Date:  2013-05-13       Impact factor: 11.205

Review 10.  Role of oxidative DNA damage in mitochondrial dysfunction and Huntington's disease pathogenesis.

Authors:  Sylvette Ayala-Peña
Journal:  Free Radic Biol Med       Date:  2013-04-18       Impact factor: 7.376

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.